Detection of microchromosomal aberrations in refractory epilepsy: a pilot study
Jacinta M McMahon1, Ingrid E Scheffer, Jillian K Nicholl
1Department of Medicine, University of Melbourne, Australia.
Summary
Microchromosomal aberrations are uncommon in patients with refractory epilepsy. While genetic anomalies were found in 10% of cases, they don't appear to be the primary cause of medication-resistant seizures.
Area of Science:
- Genetics
- Neurology
- Epilepsy Research
Background:
- Microchromosomal aberrations are linked to intellectual disability and seizures.
- The role of these aberrations in drug-resistant epilepsy is not well understood.
Purpose of the Study:
- To investigate the presence of microdeletions or microduplications in patients with epilepsy refractory to medication.
- To determine if specific microchromosomal anomalies are associated with treatment resistance.
Main Methods:
- Examined chromosomes from 20 subjects with refractory epilepsy using molecular methods.
- Utilized fluorescence in situ hybridization (FISH), multiplex ligation-dependent probe amplification (MLPA), and genome-wide oligonucleotide-array comparative genomic hybridization (oaCGH).
Main Results:
- Identified two aberrations in 20 subjects: a microdeletion at 15q13.3 and a novel microduplication at 10q21.2.
- The 15q13.3 deletion is known to be associated with seizures typically responsive to medication.
- The 10q21.2 duplication was also found in an unaffected individual, suggesting incomplete penetrance or variable expressivity.
Conclusions:
- Microchromosomal aberrations are found in a notable fraction of patients with refractory epilepsy.
- The gene content of these aberrations is unlikely to be the primary driver of medication resistance in most cases.
- Further research is needed to understand the complex genetic underpinnings of refractory epilepsy.
